Description: A phase 1, open-label, multicenter, dose-finding study of SKL27969 in patients with advanced solid tumors, central nervous system (CNS) tumors, and hematologic malignancies
Target Patient Population: All solid tumors
Study Design: Drug is given orally currently for 3 days on, 4 days off